AUSTRALIAN CLINICAL LABS LIMITED (ACL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ACL - AUSTRALIAN CLINICAL LABS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$4.59

23 Sep
2021

0.040

OPEN

$4.60

0.88%

HIGH

$4.65

830,669

LOW

$4.56

TARGET
$4.45 -3.1% downside
OTHER COMPANIES IN THE SAME SECTOR
EBO . SLA . CAJ . GXL . HSO . MPL . MVF . NHF . HLS . RHC . SHL . VRT . M7T . HLA . PSQ . SIL . PKS . ONT . DOC . NVL . AHX . ALC .
FNARENA'S MARKET CONSENSUS FORECASTS
ACL: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 29.9 47.1 xxx
DPS (cps) xxx 0.0 23.6 xxx
EPS Growth xxx 46.7% 57.5% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 9.7 xxx
Dividend Yield xxx N/A 5.2% xxx
Div Pay Ratio(%) xxx 0.0% 50.1% xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

N/A

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201920202021
EPS Basic xxxxxx29.9
DPS All xxxxxx0.0
Sales/Revenue xxxxxx641.3 M
Book Value Per Share xxxxxx40.6
Net Operating Cash Flow xxxxxx153.9 M
Net Profit Margin xxxxxx9.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021
Return on Assets xxxxxx14.36 %
Return on Equity xxxxxx80.02 %
Return on Total Capital xxxxxx36.80 %
Capex xxxxxx9.5 M
Capex % of Sales xxxxxx1.48 %
Free Cash Flow ex dividends xxxxxx102.4 M

Return on Assets

Return on Equity

Return on Total Capital

Capex

Capex % of Sales

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

27/08/2021

3

Neutral

$4.45

-3.05%

For Citi's initial response to FY21 results, see yesterday's Report.

The FY21 pro-forma profit was 6% above the mid-point of the June guidance for $82-85m. Citi's Neutral rating is unchanged.

The broker increases FY22 and FY23 EPS forecasts by 171% and 86%, due to increased forecasts for covid testing. No contribution from covid is assumed in FY24 and beyond, which is thought to present risks to the upside. The price target rises to $4.45 from $3.80.

FORECAST
Citi forecasts a full year FY22 dividend of 23.60 cents and EPS of 47.10 cents.
Citi forecasts a full year FY23 dividend of 19.10 cents and EPS of 31.90 cents.

ACL STOCK CHART